Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hyundai
Seoul, Seoul, South Koreahyundaibioscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Hyundai Bioscience has developed drug delivery technologies for broad-spectrum antiviral drugs and "pain-free" anticancer drugs, some of which are in phase 2/3 clinical stage and preclinical evaluation, focusing on autophagy enhancement and low toxicity therapies for infectious diseases and cancer.
- Therapeutic areas
- OncologyInfectious DiseasesNeurology
- Modalities
- Small moleculePolymer-drug conjugate therapyDrug delivery system
- Industry
- Biotech
02
Partnerships
DNDi (Drugs for Neglected Diseases initiative), joint development for dengue treatment
Beyond the preview
Go deeper on Hyundai.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyundai.